Prelude Therapeutics (PRLD) Preferred Stock Liabilities (2019 - 2020)
Prelude Therapeutics (PRLD) posted Preferred Stock Liabilities of $36.6 million for Q2 2020, little changed sequentially from $36.6 million in Q1 2020.
Prelude Therapeutics (PRLD) Preferred Stock Liabilities (2019 - 2020) Analysis & Trends
Prelude Therapeutics has reported Preferred Stock Liabilities for 2 years, with the latest figure at $36.6 million in Q2 2020.
- Quarterly Preferred Stock Liabilities changed N/A year-over-year to $36.6 million in Q2 2020, while the trailing twelve-month figure through Jun 2020 was $36.6 million (changed N/A YoY) and the FY2019 annual result came in at $66.4 million, changed N/A from the prior year.
- Preferred Stock Liabilities steadied at $36.6 million in Q2 2020 per PRLD's latest filing, from $36.6 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $66.4 million in Q4 2019 and troughed at $36.6 million in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Prelude Therapeutics | 442.91 Mn | 162.28 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2020 | 36.60 Mn |
| Mar 31, 2020 | 36.60 Mn |
| Dec 31, 2019 | 66.44 Mn |
| Sep 30, 2019 | 36.60 Mn |